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1 Introduction
Programs for maintaining glucose levels strictly
within normal ranges have improved the out-
come of pregnancies complicated by diabetes
mellitus [4,10,11]. The diabetic pregnancy con-
tinues to present a significant risk for congenital
malformations and neonatal morbidity [3, 14,
15, 20, 21]. It seems that further improvement
in the outcome of these pregnancies may be
obtained if normal glucose levels are accom-
plished before conception, to reduce the inci-
dence of congenital malformations [5, 15, 22]
and throughout the pregnancy to lower the
incidence of macrosomia [3, 23]. This may be
achieved with conventional two-dose or mul-
tiple insulin injections. Recently, continuous
subcutaneous insulin infusion devices have been
introduced to improve diabetic control in both
the nonpregnant and pregnant diabetic patient
[8, 18, 24]. The value of these insulin pumps
must be critically assessed. Furthermore colla-
borative efforts of the diabetology team (dia-
betologist, dietitian, obstetrician, psychologist,
social worker and nurse), as well as the patient,
through self blood glucose monitoring (SBGM)
is mandatory.
The purpose of this study was to critically com-
pare and assess glucose control and the out-
come of diabetic pregnancies, with preconcep-
tional phase counseling, by means of continu-
ous subcutaneous insulin infusion therapy to
those receiving insulin injections.
2 Material and methods
Between the years 1981-1985 eighty-three ju-
venile onset insulin dependent diabetes mellitus
(IDDM) pregnant women were treated at the
High-Risk Obstetrical Outpatient Clinic of the
Golda Meir Medical Center in association with
the Institute of Pediatric and Adolescent Endo-
crinology, Division of Juvenile Diabetes, Beilin-
son Medical Center in Israel. Fifty-two patients
contemplating pregnancy attended the precon-
ceptional clinic and were consulted by a dia-
betology team (obstetrician, diabetologist, die-
titian, psychologist, social worker and nurse).
Two patients were advised against pregnancy,
because of severe malignant retinopathy. They
were permitted to conceive following laser ther-
apy. Thirty-one patients who attended the clinic
at different stages of pregnancy were deleted
from the study. All patients completed their
pregnancies and had delivered by the time of
this report. In order to obtain optimal diabetes
control before conception and to maintain nor-
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mal glucose levels throughout pregnancy the
insulin need based on body weight was calcu-
lated (0.6 U/kg/24h = pregestational; 0.7 U/
kg/24h = first trimester; 0.8 U/kg/24h = se-
cond trimester; 0.9 U/kg/24h = third trimester;
1.0 U/kg/24h = term). The total amount of in-
sulin required was divided into insulin amounts
that provided the basal needs and the bolus
needs. Continuous subcutaneous insulin infu-
sion pumps (CSIIP), Auto Syringe AS-G6, Me-
dix 209/100 Insulin Pump, and recently the
Nordisk Infuser were used in 18 women. Thirty-
four women received three to four injections a
day of intermediate (NPH) and short-acting
(regular) insulin. All patients were advised to
adhere closely to their strict, prescribed diet,
(American Diabetes Association diets
1800-2200 Kcal/day), divided into three meals
and two to three snacks. All patients performed
self blood glucose monitoring 6 — 8 times a day
using glucose meters and charted the blood
glucose levels. Hemoglobin Ai was measured
twice monthly by cation exchange column chro-
matography using microcolumn fast hemoglo-
bin test system (Isolab, Akron, OHIO, USA).
The normal range in our laboratory is 6.0 — 7.5
percent.
After the glycosylated hemoglobin levels in the
patients were below 8.5%, which was the cutoff
line for increased risk of malformations in MIL-
LER'S report [14], they were encouraged to con-
ceive. In order to facilitate the very early diag-
nosis of pregnancy, patients were asked to
measure basal body temperature through each
menstrual cycle. The beta subunits of HCG was
determined after a month had elapsed since the
last menstrual period; if the test was negative
it was repeated at weekly intervals while amen-
orrhea persisted.
Antepartum surveillance included: monthly ul-
trasound imaging for fetal growth or anomalies
after 8 weeks' gestation [16], daily fetal move-
ments count after 20 — 22 weeks' gestation [19],
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and weekly fetal biophysical profile after 28
weeks' gestation [13]. Fetal lung maturity was
evaluated by means of lung profile [12] and
amniotic fluid microviscosity [1]. Timing and
route of delivery were individualized according
to maternal and fetal conditions.
3 Results
Table I presents diabetes control and insulin
requirements in the 52 IDDM pregnant women
treated prior to conception with CSIIP or with
intensified insulin therapy.
In both groups mean blood glucose levels and
mean HbAi were elevated at the initial clinic
visit prior to pregnancy, but normal HbAi as
well as physiologic blood glucose levels were
achieved at conception and by the first trimester
and maintained throughout the pregnancy.
Nevertheless, in spite of the almost similar
degree of improved diabetic control in both
groups significantly lower mean daily insulin
doses were required during the second
(50 ± 4 U; p < 0.05) and third trimesters
(62 ± 5 U; P < 0.001) of pregnancy by patients
using infusion pumps in comparison to patients
receiving intensified insulin therapy. Maternal
information concerning the 52 gestations with
preconceptional therapy is presented in table
II. Patients using CSIIP were older, of higher
parity and had a longer duration of diabetes as
well as more frequent secondary complications.
According to White's classification [25] 66.6%
of pump users were classified in groups D — R
whereas only 26.5% of the patients receiving
insulin injections were in the same White's
groups. The frequencies of pre-eclampsia and
cesarean deliveries among pump users were
higher than in patients managed with insulin
injections.
In two patients treated with intensified insulin
regimen hypoglycemia occured overnight in the
3rd trimester. In one woman on the pump, tem-
porary hypoglycemia occured in the first tri-
mester shortly after the pump's installation.
Neonatal data are presented in table III. Mean
gestational age, mean birth weights, Apgar
scores and neonatal complications were not
significantly different in both groups. No mal-
formations were detected in offspring of both
groups.
Table II. Maternal information on 52 IDDM gestants.
Variable
Mean maternal age (yr)









Mean duration of pregnancy (wks)
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Table ΙΠ. Neonatal data on 52 infants of IDDM mothers with preconceptional therapy.
Variable
Mean gestational age (wk)
Mean birth weight (gm)
Mean 1 minute Apgar
Mean 5 minutes Apgar
Hypoglycemia [< 30 mg per 100 ml] (%)
Hypocalcemia [< 8 mg per 100 ml] (%)
Hyper bilirubinemia [> 15 mg per 100 ml] (%)






































* Statistical analysis by Students' t test.
Abbreviations used: CSIIP — Continuous Subcutaneous Insulin Infusion Pump
IIT — Intensified Insulin Therapy
NS - Not Significant
4 Comment
The emerging evidence that congenital malfor-
mations in pregnancy complicated by diabetes
may be linked to disturbances in maternal glu-
cose metabolism during the period of embryog-
enesis [2, 9, 15, 20] provides a case for the
institution of strict diabetic control prior to
conception. Clinical evidence to support that
position already has been documented [5, 14,
22]. The need is underscored by the fact that
organogenesis is completed by the 6th or 7th
week of gestation in most of the structures in
which diabetes related birth defects tend to
occur [15], which is before the patient may
know that she is pregnant and has not yet come
to medical supervision. Normal glucose levels
can be achieved in pregnant diabetic patients
prior to conception and maintained throughout
pregnancy either by conventional two-dose or
multiple insulin injections [4, 6] as well as with
the use of the newer insulin infusion pumps [8,
17,18]. Optimal therapy necessitates individual-
ization. Beyond the 28th week, when anti-insu-
lin factors attain peak intensity, most pregnant
women in our Center obtain additional multiple
(regular) insulin injections. In fact, the precise
doses are adjusted to achieve good metabolic
control. Moreover, we recommend CSIIP in
selected, well motivated patients with severe
diabetes contemplating pregnancy.
Our findings reflect the fact that successful glu-
cose control can be obtained in pregnant dia-
betic patients prior to and throughout preg-
nancy, with the use of CSIIP as well as with
intensified insulin therapy. The cost/benefit ra-
tio is, in favor of IIT because it is cheaper to
provide. It is necessary to note that patients
with intensified insulin therapy required signifi-
cantly higher doses of insulin during the second
and third trimester of pregnancy in comparison
to pump users. Indeed, excessive insulin doses
becomes a concern since the consequences of
excessive insulin may compromise both the
mother and the fetus with hypoglycemia and
by suppressing the levels of alternate fetal fuels,
such as plasma beta hydroxybutyrate [7]. In
fact, patients on intensified insulin therapy in
this study had occasional overnight hypoglyce-
mia, while pump users achieved normal glucose
levels without overt insulin administration.
Insulin pumps were advantageous during inter-
current illness, as adjustment to rapid changes
in insulin requirements could be made easily
and effectively, even in the home environment.
Patients accepted the pump system well; mainly
the smaller, compact devices were more accept-
able. No serious complications resulted from
the continuous subcutaneous infusion system
during this study. One pump underwent a
mechanical "run away", and insulin administra-
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tion was discontinued temporarily. The patient
was given I. V. glucose 10% and extra snacks
until normal glucose levels were achieved when
normal insulin/diet schedule was resumed.
In spite of the successful CSIIP therapy in this
series it can not be recommended for every
diabetic patient prior to and during gestation,
and it should remain an investigational tool.
Specific selective criteria for well motivated
patients need to be established. Although pump
users in this group had a higher rate of pre-
eclampsia which contributed in part to the
higher cesarean section rates, we consider that
more of these patients had more severe diabetes
(66% - White's class D-R).
Our data emphasize the improved metabolic
control achieved by either technique in this
series. We feel that establishment of tight meta-
bolic control before conception and during
pregnancy contributed to better control of dia-
betes, particularly at the crucial time of concep-
tion. The reduction of congenital malformation
rates due to preconceptional diabetic control
must further be studied and proven.
We must conclude on the basis of this study,
that in spite of the advantageous use of CSIIP
in selected cases, the disadvantages of these
devices, as well as good results achieved with
IIT, favor the use of the latter in the treatment
of the pregnant diabetic.
Summary
Preconceptional diabetes management is an important
prerequisite for pregnancy planning and its value has
been well-documented. Glucose control and the outcome
of pregnancy, managed in the preconceptional period,
with continuous subcutaneous insulin infusion therapy
to those receiving insulin injections are compared.
Fifty-two juvenile onset insulin dependent diabetic
women contemplating pregnancy were regularly con-
sulted by a diabetology team starting at least two months
before conception. Glucose control was achieved by
continuous subcutaneous insulin infusion pumps
(CSIIP) in 18 patients, and 34 women received intensive
insulin therapy (IIT). In both groups, normal glucose
levels and normal HbAi were achieved at conception,
maintained during the period of organogenesis and
throughout pregnancy.
In view of the fact that perinatal results, such as the
occurrence of malformations, mean gestational age,
mean birth weight and neonatal complications were not
significantly different in both groups, we believe that
both methods are equally effective. Consequently, the
less costly and yet effective IIT may be the method of
choice, while the more expensive pump should be used
mainly in selected cases.
Keywords: Diabetes mellitus, diabetic pregnancy, insulin infusion pump, preconceptional diabetes control, preg-
nancy planning in diabetics.
Zusammenfassung
Diabeteseinstellung vor der Konzeption bei insulinabhängi-
gen Patientinnen mit kontinuierlicher subkutaner Insulin-
infusion
Die Bedeutung der Diabeteseinstellung vor einer geplan-
ten Schwangerschaft ist bekannt und nachgewiesen. Be-
reits vor der Konzeption erhielten die Frauen entweder
eine kontinuierliche subkutane Insulininfusionstherapie
oder Insulininjektionen in üblicher Weise. Wir haben
diese beiden Kollektive hinsichtlich ihrer Blutzuckerspie-
gel und der Schwangerschaftsverläufe miteinander ver-
glichen.
50 Frauen mit insulinabhängigem juvenilen Diabetes,
die eine Schwangerschaft planten, wurden mindestens 2
Monate vor Konzeption von Diabetologen beraten. Bei
18 Patientinnen wurde der Glukosespiegel mit subkuta-
nen Insulininfusionen über eine Pumpe eingestellt, 34
Patientinnen erhielten Insulingaben in üblicher Form,
wurden aber strenger eingestellt. In beiden Gruppen
wurde eine Normoglykämie und ein normaler Hb Ai-
Wert bei Konzeption erreicht, die auch in der Phase der
Organogenese und über die gesamte Schwangerschaft
aufrechterhalten werden konnten.
Im Hinblick auf verschiedene perinatale Parameter wie
Häufigkeit von Mißbildungen, durchschnittliches Gesta-
tionsalter und Geburtsgewicht sowie neonatale Kompli-
kationen gab es zwischen beiden Gruppen keine signifi-
kanten Unterschiede, so daß wir glauben, daß beide
Methoden gleich effektiv sind. Die weniger kosteninten-
sive und dennoch effektive strenge Einstellung mit Insu-
lininjektionen sollte die Methode der Wahl sein, wäh-
rend die teure Insulinpumpe hauptsächlich ausgewählten
Fällen vorbehalten sein soll.
Schlüsselwörter: Diabeteseinstellung vor Konzeption, Diabetes mellitus, Diabetes und Schwangerschaft, Insulin-
infusionspumpe, Schwangerschaftsplanung bei Diabetes.
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Resume
Contröle du diabete avant la conception chez les patientes
insulino-dependantes par perfusion continue d'Insuline
sous-cutanee
L'equilibre du diabete avant la conception est une neces-
site importante pour la plannification de la grossesse et
sa valeur est bien documentee. On compare le contröle
glycemique et le devenir de la grossesse chez des patientes
prises en charge a la periode pre-conceptionnelle ä aide
de perfusion continue d'Insuline sous-cutanee a ceux de
patientes traitees par injections d'Insuline.
Cinquante deux femmes atteintes d'un diabete insulino-
dependant a debut juvenile, souhaitant une grossesse
ont etc suivies regulierement par une equipe diabetologi-
que en debutant au moins deux mois avant la concep-
tion. Chez 18 patientes, le contröle glycemique etait
realise ä aide de pompes ä perfusion continue d'Insuline
sous-cutanee (CSIIP), chez 34 de contröle etait realise
par une augmentation de l'insulinotherapie (ITT). Dans
les deux groupes, ä la conception une glycemie normale
et une HbAi normale etaient obtenues et maintenues
pendant toute la periode d'organogenese et tout au long
de la grossesse.
Nous pensons que les 2 methodes sont equivalentes dans
la mesure ou les resultats perinataux, comme le taux
de malformations, Page gestationnel moyen, le poid de
naissance moyen et les complications neonatales ne sont
pas differents de fagon significative dans les deux grou-
pes.
Par consequent, la methode de choix est ITT qui est
la plus economique et neanmoins aussi efflcace, alors
que les pompes, beaucoup plus couteuses, devraient etre
reservees principalement a des cas selectionnes.
Mots-cles: Contröle pre-conceptionnel du diabete, diabete sucre, grossesse chez la diabetique, plannification des
grossesses chez la diabetique, pompe a perfusion d'Insuline.
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